Derry C Roopenian
Overview
Explore the profile of Derry C Roopenian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
5159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wells A, Wilson J, Heuer S, Sears J, Wei J, Pandey R, et al.
PLoS One
. 2024 Mar;
19(3):e0299595.
PMID: 38451972
Objective: Glycolytic inhibition via 2-deoxy-D-glucose (2DG) has potential therapeutic benefits for a range of diseases, including cancer, epilepsy, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA), and COVID-19, but the...
2.
Cowan T, Sundberg J, Roopenian D, Sproule T, Murrell D
J Eur Acad Dermatol Venereol
. 2024 Feb;
38(8):e719-e721.
PMID: 38376117
No abstract available.
3.
Sproule T, Wilpan R, Wilson J, Low B, Kabata Y, Ushiki T, et al.
PLoS One
. 2023 Oct;
18(10):e0293218.
PMID: 37883475
The Lamc2jeb junctional epidermolysis bullosa (EB) mouse model has been used to demonstrate that significant genetic modification of EB symptoms is possible, identifying as modifiers Col17a1 and six other quantitative...
4.
Functional analysis of Collagen 17a1: A genetic modifier of junctional epidermolysis bullosa in mice
Sproule T, Wilpan R, Low B, Silva K, Reyon D, Joung J, et al.
PLoS One
. 2023 Oct;
18(10):e0292456.
PMID: 37796769
Previous work strongly implicated Collagen 17a1 (Col17a1) as a potent genetic modifier of junctional epidermolysis bullosa (JEB) caused by a hypomorphic mutation (Lamc2jeb) in mice. The importance of the noncollagenous...
5.
Wilson J, Wei J, Daamen A, Sears J, Bechtel E, Mayberry C, et al.
iScience
. 2023 Aug;
26(9):107487.
PMID: 37636066
Aberrant metabolic demand is observed in immune/inflammatory disorders, yet the role in pathogenesis remains unclear. Here, we discover that in lupus, activated B cells, including germinal center B (GCB) cells,...
6.
Sproule T, Philip V, Chaudhry N, Roopenian D, Sundberg J
PLoS One
. 2023 Jul;
18(7):e0288263.
PMID: 37437067
Epidermolysis Bullosa (EB) is a group of rare genetic disorders that compromise the structural integrity of the skin such that blisters and subsequent erosions occur after minor trauma. While primary...
7.
Wells A, Wilson J, Sears J, Wei J, Heuer S, Pandey R, et al.
bioRxiv
. 2023 May;
PMID: 37162857
Objective: Glycolytic inhibition via 2-deoxy-D-glucose (2DG) has potential therapeutic benefits for a range of diseases, including cancer, epilepsy, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA), and COVID-19, but the...
8.
Bern M, Nilsen J, Ferrarese M, Sand K, Gjolberg T, Lode H, et al.
Sci Transl Med
. 2020 Oct;
12(565).
PMID: 33055243
Needle-free uptake across mucosal barriers is a preferred route for delivery of biologics, but the efficiency of unassisted transmucosal transport is poor. To make administration and therapy efficient and convenient,...
9.
Hubbard J, Pyzik M, Rath T, Kozicky L, Sand K, Gandhi A, et al.
J Exp Med
. 2020 Jul;
217(10).
PMID: 32658257
IgG immune complexes (ICs) promote autoimmunity through binding fragment crystallizable (Fc) γ-receptors (FcγRs). Of these, the highly prevalent FcγRIIa (CD32a) histidine (H)-131 variant (CD32aH) is strongly linked to human autoimmune...
10.
Nilsen J, Trabjerg E, Grevys A, Azevedo C, Brennan S, Stensland M, et al.
Commun Biol
. 2020 Apr;
3(1):181.
PMID: 32313072
Albumin has an average plasma half-life of three weeks and is thus an attractive carrier to improve the pharmacokinetics of fused therapeutics. The half-life is regulated by FcRn, a cellular...